Loading...
01/11 04:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with record revenue and EBITDA growth, surpassing guidance. Despite cautious client spending due to macroeconomic factors, AI tools are driving double growth rates among adopters. The company's robust share repurchase program and stable margins further strengthen its position. While guidance is conservative, the overall sentiment remains positive due to strong client loyalty and operational efficiency. The Q&A session highlighted enthusiasm for AI and strategic investments, suggesting potential for future growth.
Revenue (Q4 FY25) $138,300,000, up 17% year-over-year, exceeding guidance due to strategic shift to multi-module integrated offerings.
Revenue (Full Year FY25) $570,400,000, up 20% year-over-year, driven by larger deal sizes and efficient launch timelines.
Adjusted EBITDA (Q4 FY25) $69,700,000, with a margin of 50%, compared to $56,400,000 and 48% margin in the prior year.
Adjusted EBITDA (Full Year FY25) $313,800,000, up 36% year-over-year, with a margin of 55%, up from 48% the prior year.
Free Cash Flow (Q4 FY25) $97,000,000, up 56% year-over-year, reflecting strong operational performance.
Free Cash Flow (Full Year FY25) $266,700,000, up 50% year-over-year, indicating improved cash generation.
Net Revenue Retention Rate (Q4 FY25) 119% on a trailing twelve month basis, with top 20 customers at 123%, showing strong customer loyalty.
Customers contributing at least $500,000 in revenue (Q4 FY25) 116 customers, a 17% increase from 99 customers a year ago, accounting for 84% of total revenue.
Non-GAAP Gross Margin (Q4 FY25) 91%, flat year-over-year, indicating stable cost management.
Non-GAAP Gross Margin (Full Year FY25) 92%, up from 91% last year, reflecting operational efficiency.
AI Tools: Doximity's AI tools, including Doximity GPT, have seen significant adoption, with a focus on specialty-specific applications that help physicians manage patient information more efficiently.
Workflow Tools: The company reported over 620,000 unique active prescribers using its workflow tools, which include telehealth, fax, scheduling, and AI tools.
Market Growth: Doximity's top 20 clients grew revenue by 23% in fiscal 2025, indicating strong market positioning and client retention.
Client Portal Insights: The rollout of the client portal has enhanced client engagement and interest in AI-powered offerings, leading to increased spending.
Revenue Growth: Doximity achieved $138 million in revenue for Q4 FY25, exceeding guidance by 4%, and $570 million for the full fiscal year, a 20% year-on-year increase.
Free Cash Flow: The company generated $97 million in free cash flow for Q4, a 56% increase year-on-year, and $267 million for the full fiscal year, up 50%.
Strategic Shift: Doximity has shifted towards multi-module integrated offerings, which have driven larger deal sizes and improved revenue predictability.
AI Investment: The company plans to increase investments in AI to enhance tools for members and improve operational efficiency.
Macro Economic Risks: There is material policy uncertainty that could impact client spending, leading to a cautious outlook for revenue growth.
Client Spending: Clients are showing cautious optimism but are also being prudent with their budgets due to macroeconomic uncertainties.
Regulatory Risks: Potential changes in drug pricing policies could affect client budgets and spending patterns.
Supply Chain Challenges: No specific supply chain challenges were mentioned, but the overall economic environment may influence operational costs.
Competitive Pressures: Doximity faces competition from other digital marketing platforms, and clients are shifting budgets towards proven high ROI channels.
AI Investment Risks: Investments in AI are still in early stages, and the long-term impact on margins and efficiency is uncertain.
Market Growth Rate: The expected growth rate for the Pharma HCP digital market is cautious, with guidance reflecting a potential slowdown.
Upsell Variability: Upsell opportunities are more variable, and there is uncertainty regarding client budget allocations for the upcoming year.
Revenue Growth: Doximity delivered $138,000,000 in revenue for Q4 FY25, exceeding guidance by 4%. Full year revenue reached $570,000,000, growing 20% year on year.
Adjusted EBITDA Margin: Adjusted EBITDA margin for Q4 was 50%, exceeding guidance by 10%. Full year adjusted EBITDA margin was 55%, up from 48% the previous year.
Client Growth: Top 20 clients grew 23% in FY25, indicating strong demand and retention.
AI Investments: Doximity plans to increase investments in AI to enhance tools for members and clients, aiming for greater efficiency and improved offerings.
Multi-Module Offerings: The strategic shift to multi-module integrated offerings has driven larger deal sizes and earlier program launches, contributing to revenue growth.
Client Portal Insights: The client portal has improved visibility and engagement, allowing clients to track ROI and optimize their programs.
Q1 FY26 Revenue Guidance: Expected revenue range of $139,000,000 to $140,000,000, representing 10% growth at the midpoint.
FY26 Revenue Guidance: Expected revenue range of $619,000,000 to $631,000,000, representing 10% growth at the midpoint.
Q1 FY26 Adjusted EBITDA Guidance: Expected adjusted EBITDA in the range of $71,000,000 to $72,000,000, representing a 51% adjusted EBITDA margin.
FY26 Adjusted EBITDA Guidance: Expected adjusted EBITDA in the range of $333,000,000 to $345,000,000, representing a 54% adjusted EBITDA margin.
Market Growth Rate: Pharma HCP digital market expected to grow at 5% to 7%, with Doximity projected to grow at roughly twice the market rate.
Subscription Revenue Visibility: Just under 70% of initial subscription-based revenue guidance is under contract.
Share Repurchase Program: During the fourth quarter, Doximity repurchased $26,800,000 worth of shares. For the full fiscal year, the total repurchased amount was $116,200,000 at an average price of $33.73. As of March 31, there remains $424,000,000 in the existing repurchase program.
The earnings call reveals strong financial performance with a 56% EBITDA margin and 15% revenue growth guidance. Product development is promising with AI investments and Pathway acquisition. Market strategy is robust, focusing on AI and health systems. Expenses are controlled with margins expected to remain stable. Shareholder return is not explicitly mentioned, but positive cash flow is anticipated. Q&A insights show optimism in AI and integrated programs, despite some uncertainties in policy impacts. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
Doximity's earnings call summary and Q&A section indicate strong financial performance, with revenue and EBITDA exceeding guidance, and promising AI investments. Despite cautious guidance due to policy uncertainty, the company's robust client engagement, strategic AI integration, and successful product portfolio suggest a positive outlook. The Pathway acquisition's minimal cost impact and high engagement metrics further support this view. Overall, the company's strategic initiatives and market growth potential outweigh any uncertainties, leading to a positive sentiment.
Doximity shows strong financial performance with significant revenue and EBITDA growth, a robust client retention rate, and successful AI tool adoption. Despite some uncertainties in AI investment payback and macroeconomic impacts, the company's strategic initiatives and share repurchase program indicate confidence. The Q&A highlights strong client interest in AI and no signs of market slowdown. The positive guidance and financial results, along with a proactive shareholder return plan, suggest a positive stock price movement in the short term.
The earnings call reflects strong financial performance with record revenue and EBITDA growth, surpassing guidance. Despite cautious client spending due to macroeconomic factors, AI tools are driving double growth rates among adopters. The company's robust share repurchase program and stable margins further strengthen its position. While guidance is conservative, the overall sentiment remains positive due to strong client loyalty and operational efficiency. The Q&A session highlighted enthusiasm for AI and strategic investments, suggesting potential for future growth.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
